Trials / Completed
CompletedNCT04175262
Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments
Clinical Effectiveness of Second-Line Sunitinib Following Immune-oncologic (IO) Therapy in Patients With Metastatic Renal Cell Carcinoma in the International Metastatic Renal Cell Carcinoma Database (IMDC)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 102 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study aims to assess clinical outcomes in mRCC patients treated with sunitinib in second-line following IO therapy in real world clinical practices.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sunitinib | Patients to receive sunitinib as second line therapy for mRCC |
Timeline
- Start date
- 2019-10-31
- Primary completion
- 2020-03-09
- Completion
- 2020-03-09
- First posted
- 2019-11-25
- Last updated
- 2023-05-03
- Results posted
- 2021-04-02
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT04175262. Inclusion in this directory is not an endorsement.